Acesso livre
Acesso livre

Vacinas

M-A | Miopericardite após vacinação contra COVID-19 e vacinação não relacionada a COVID-19.

19 Abr, 2022 | 12:41h

Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis – The Lancet Respiratory Medicine

Comentários:

Myopericarditis following COVID-19 vaccination is rare, finds international study – The Lancet

Myopericarditis after COVID-19 vaccination: unexpected but not unprecedented – The Lancet Respiratory Medicine

Study explores myopericarditis incidence and COVID-19 vaccination – News Medical

 

Comentário no Twitter

 

Análise observacional em Israel mostrou que a 4ª dose da vacina da Pfizer pode reduzir o risco de curto prazo dos desfechos adversos relacionados a Covid-19.

18 Abr, 2022 | 15:31h

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting – New England Journal of Medicine

Editorial: Covid-19 Boosters — Where from Here?

Conteúdos relacionados:

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter

 

Estudo randomizado | Eficácia, segurança e imunogenicidade de uma vacina de enterovírus 71 inativado em bebês e crianças.

18 Abr, 2022 | 15:26h

Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Estudo randomizado | Vacinação em dose única contra o HPV se mostrou efetiva entre mulheres jovens na África.

14 Abr, 2022 | 17:07h

Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women – NEJM Evidence

Comunicado de imprensa:

Study boosts support for single-dose HPV vaccine regimen – University of Washington

One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer – World Health Organization

Conteúdo relacionado: Three-year follow-up of 2-dose versus 3-dose HPV vaccine

 

Comentário no Twitter (fio – clique para saber mais)

 

M-A | Padrões de trombose e desfecho clínico da trombocitopenia trombótica imune induzida por vacina contra COVID-19.

11 Abr, 2022 | 12:58h

Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis – International Journal of Infectious Diseases

Conteúdos relacionados:

Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.

Review: Vaccine-induced immune thrombotic thrombocytopenia.

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

COVID-19: diretriz conjunta do ECDC e EMA sobre a 4ª dose de vacinas de mRNA.

8 Abr, 2022 | 21:56h

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Conteúdos relacionados:

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter (fio – clique para saber mais)

 

Perspectiva | As evidências sobre a 4ª dose das vacinas contra Covid & a questão complicada dos limites de idade.

6 Abr, 2022 | 12:53h

The Evidence On 4th Doses of Covid Vaccines & the Thorny Question of Age Thresholds – Absolutely Maybe Blog, by Hilda Bastian

Conteúdos relacionados:

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter

 

Estudo randomizado | Eficácia, segurança e imunogenicidade da vacina de DNA contra SARS-CoV-2 (ZyCoV-D).

6 Abr, 2022 | 12:48h

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India – The Lancet

Comentário convidado: DNA vaccines join the fight against COVID-19 – The Lancet

 

Comentário no Twitter

 

Estudo de caso-controle | Em crianças de 5 a 11 anos de idade, a vacina da Pfizer mostrou efetividade de 68% contra internação causada pela variante Ômicron.

1 Abr, 2022 | 12:29h

BNT162b2 Protection against the Omicron Variant in Children and Adolescents – New England Journal of Medicine

Comentário: COVID vaccination of children age 5-11 cut omicron hospitalizations by 68% – Children’s Hospital Boston

Conteúdo relacionado: [Preprint] Study shows significantly reduced effectiveness of the Pfizer vaccine in children 5 to 11 after the emergency of the Omicron variant.

 

Comentário no Twitter

 

[Preprint] Estudo de coorte retrospectiva | 2º reforço de vacina e mortalidade por Covid-19 em adultos de 60 a 100 anos de idade.

31 Mar, 2022 | 13:44h

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old – Research Square

Comentários:

Huge Study Finds Second COVID-19 Booster is ‘Life-saving’ for Over 60s – Health Policy Watch

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly – News Medical

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.